The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 05, 2021
Filed:
Dec. 21, 2018
Applicant:
Amgen Inc., Thousand Oaks, CA (US);
Inventors:
Sean Caenepeel, Thousand Oaks, CA (US);
Jude Canon, Marina Del Ray, CA (US);
Paul Hughes, Santa Monica, CA (US);
Jonathan D. Oliner, Garrett Park, MD (US);
Richard J. Rickles, Arlington, MA (US);
Anne Y. Saiki, Moorpark, CA (US);
Assignee:
AMGEN INC., Thousand Oaks, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/451 (2006.01); A61K 31/166 (2006.01); A61K 31/365 (2006.01); A61K 31/4045 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/496 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/635 (2006.01); A61K 31/704 (2006.01); A61K 31/706 (2006.01); A61K 31/7068 (2006.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/451 (2013.01); A61K 31/166 (2013.01); A61K 31/365 (2013.01); A61K 31/4045 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61K 31/635 (2013.01); A61K 31/704 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01);
Abstract
The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.